Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double-blind, placebo-controlled parallel group, single centre study evaluating neurohumoral, haemodynamic and renal effects of UrocortiN 2 administered In addition to COnventional care compared with placebo administered in addition to standaRd care in subjects with Acute DecompeNsated Heart Failure.

Trial Profile

A randomised, double-blind, placebo-controlled parallel group, single centre study evaluating neurohumoral, haemodynamic and renal effects of UrocortiN 2 administered In addition to COnventional care compared with placebo administered in addition to standaRd care in subjects with Acute DecompeNsated Heart Failure.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Urocortin 2 (Primary)
  • Indications Decompensated heart failure
  • Focus Pharmacodynamics
  • Acronyms UNICORN
  • Most Recent Events

    • 17 May 2012 Results have been reported in a Neurocrine Biosciences media release.
    • 02 May 2012 Status changed from recruiting to completed, according to a Neurocrine Biosciences media release.
    • 03 May 2011 As of mid-April, 43 out of 50 patients have been enrolled, according to a Neurocrine Biosciences media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top